· A Patent Application has been filed
North Carolina State University is seeking for entrepreneurs to assist in the development and commercialization of a novel synergistic transcutaneous immunotherapy.
It is important to prevent cancer relapse after resection of tumors, as a rapid cancer progression may occur due to a surgically induced inflammatory response. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. A new class of drugs that block PD-1, the PD-1 inhibitors, activate the immune system to attack tumors and are therefore used with varying success to treat some types of cancer. The delivery of PD-1 Antibodies for cancer treatment has met with varying success.
Researchers at North Carolina State University have developed an inflammation-triggered combination delivery of anti-PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) for post-surgery treatment. The delivery carrier, designated as DNA “nanoclew” (DNC), is weaved through the rolling circle amplification using a CpG ODN-encoded template. After injection into the tumor resection sites, TGMS nanoparticles are disassembled upon the digestion of inflammatory-associated proteases to release the caged enzyme, allowing fragmentation of DNCs into CpG ODNs and releasing aPD-1. Using the mouse melanoma-tumor resection model, we demonstrate that a systemic antitumor immune response is generated, significantly inhibiting tumor relapse and metastasis compared to the conventional delivery modalities.
· Effective localized delivery of Anti-PD1 antibodies
· Reduced immunosuppression at the local site
· Enhanced effective T Cell immunity
About the Lead Inventor
Dr. Zhen Gu obtained Ph.D. at the University of California, Los Angeles, under the guidance of Prof. Yi Tang in the Department of Chemical and Biomolecular Engineering. He was a postdoctoral associate working with Prof. Robert Langer at MIT and Harvard Medical School during 2010 to 2012. He is currently an Associate Professor and founding Director of the Translational Innovation (TraIn) Professional Science Master program in the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University. He also holds joint positions in the Eshelman School of Pharmacy and Department of Medicine at UNC. His group studies controlled drug delivery, bio-inspired materials and nanobiotechnology. Prof. Gu is the recipient of the Sloan Research Fellowship (2016), Pathway Award (2015) and Junior Faculty Award (2014) of the American Diabetes Association (ADA), Young Innovator Award in Cellular and Molecular Engineering of the Biomedical Engineering Society (BMES, 2015) and the Sigma Xi Young Faculty Research Award (2014). MIT Technology Review listed him in 2015 as one of the global top innovators under the age of 35 (TR35). GOOD Magazine listed him in 2016 as one of GOOD 100- “100 individuals who are improving the world through creativity and innovation”.